To evaluate the efficacy of ralizumab combined with Traditional Chinese medicine in the treatment of macular edema secondary to retinal vein occlusion based on a real-world study

Evaluation the therapeutic effect of Wenyang Jianpi Lishi Prescription combined with anti-VEGF drugs in the treatment of macular edema secondary to retinal vein occlusion due to spleen deficiency phlegm-dampness

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005968

Enrollment

Unknown

Registered

2022-05-04

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

The control group:Compound Xueshuantong 1.5g Po tid and Maizhiling tablet 0.3g bid were taken orally for 6 months.

The control group and the treatment group:Intravitreal injection of ramizumab

the treatment group:Orally warm Yang invigorating spleen and invigorating dampness prescription granules, each dose divided into two portions, adding 100ml warm water once for rinsing, 2 times a day.

The control group and the treatment group:Retinal laser photocoagulation

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 18-80 years old RVO secondary macular edema, TCM syndromes conform to spleen deficiency phlegm-dampness type

Exclusion criteria

Exclusion criteria: 1. RVO patients are younger than 18 years old or older than 80 years old; 2. TCM syndromes of RVO patients do not conform to the type of spleen deficiency and phlegm-dampness; 3. RVO patients have severe proliferative retinopathy or retinal detachment; 4. Patients with RVO receive systemic or local (vitreous injection) hormones.

Design outcomes

Primary

Measure	Time frame
best corrected visual acuity,BCVA;Number of ralizumab injections within 1 year;Number of ralizumab injections within 1 year;Macular edema;	—

Secondary

Measure	Time frame
Macular pucker;Vitreous hemorrhage;	—

Countries

China

Contacts

Public ContactZhihua Shen

szhihua2006@126.com13410527510

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026